HemoCue glucose value was ϳ10% lower than the glucose value of the 0% MetHb sample; and at a measured MetHb value of 30% (i.e., approximately the concentration in our patient), the HemoCue glucose value fell by one-third. Minimal change was seen with the other glucose meters or, as described above, with the main laboratory method. These results confirm that MetHb interferes with the HemoCue glucose analyzer. The HemoCue glucose result for the 0% MetHb sample was higher than any of the results found with the other methods, again in keeping with other studies (1) (2) (3) . The measured MetHb values agree well with the nominal values.
We have demonstrated that MetHb interferes with the HemoCue B-Glucose Analyzer, and we speculate that this error originates either from direct interference with the color development of the tetrazolium salt or, more likely, from the absorption of the MetHb species at Ͼ630 nm (14 ) . Previously, Zijlstra et al. (15 ) suggested photometric interference for the differences they observed between adult and neonatal blood with the HemoCue analyzer.
We recommend that the HemoCue B-Glucose Analyzer should not be used for patients with MetHb concentrations Ͼ10% and that an alternative method should be used for glucose determination in such patients.
Rapid steroid hormone immunoassays often agree poorly, especially at normal and low concentrations (1) (2) (3) (4) . These problems result from low assay specificity, inadequate standardization, and poor optimization of the methods over the large range of concentrations seen clinically (5) (6) (7) . These systems are often unsuitable for clinical applications that require a low detection limit, such as the following: (11, 12 ) . Furthermore, limits of detection determined with the zero calibrator are generally far below the lowest concentration that can be reliably quantified in human serum [functional sensitivity (13, 14 ) or limit of quantitation (LOQ) (15 ) ].
In this study, we analyzed and compared detection limits and functional sensitivities for nine estradiol (E 2 ) and eight progesterone (P) immunoassays.
Between 1997 and 2001, we tested nine automated multianalyte systems for E 2 and/or P measurements: ACS-180 (Bayer Diagnostics), Advia-Centaur (Bayer Diagnostics), Vitros ECi (Ortho-Clinical Diagnostics), Architect i2000 (Abbott Laboratories), Kryptor (Brahms), Immuno-1 (Bayer Diagnostics) for E 2 and P; IMx (Abbott Laboratories), Elecsys 2010 (Roche Diagnostics) for E 2 ; and AxSYM (Abbott Laboratories) for P. All of these nonisotopic immunoassays are based on competitive methods and involve detection by direct (Architect i2000, Advia-Centaur, ACS-180) or indirect (Vitros ECi) chemiluminescence, electrochemiluminescence (Elecsys 2010), fluorescence (IMx, AxSYM), spectrophotometry (Immuno-1), or Trace technology (Kryptor). We have also studied one direct RIA for E 2 and P (Coatria 125 I; BioMérieux).
We determined the detection limit, defined as the concentration at 2 SD above the mean signal value of the zero calibrator (free of analyte) from each assay (measured 10 times within a single analytical run), with respect to the concentration for another calibrator concentration. If no zero calibrator was included in the calibration set (most of the systems studied required master curve calibration carried out by the manufacturer and required only two calibrators to adjust the master curve), we asked the Clinical Chemistry 48, No. 3, 2002 manufacturer to supply it. We determined the functional sensitivity (not usually determined by the manufacturer), defined as the lowest concentration of analyte that can be measured with a run-to-run imprecision (CV) of 20% (13 ) . The interassay precision profile was used to determine, for each analyte and each assay, the concentration corresponding to CV of 20%. This profile was determined with pools of sera covering the calibration curves, analyzed (once for each analytical run) over 30 days with two different lots of reagent, according to the protocol of Spencer et al. (14 ) .
Detection limits were 11 pmol/L (3 pg/mL; Kryptor) to 77 pmol/L (25 pg/mL; Architect i2000) for E 2 and 0.19 nmol/L (0.06 ng/mL; Kryptor) to 0.17 ng/mL (0.54 nmol/L; AxSYM) for P ( Table 1 ). All immunoassays except E 2 Architect and E 2 IMx had detection limits close to 37 pmol/L (10 pg/mL) for E 2 and close to 0.32 nmol/L (0.1 ng/mL) for P. The values obtained in our study were close to those given by the manufacturers (cited in package inserts). Only E 2 Architect i2000 had a detection limit (77 pmol/L; 25 pg/mL) different from that given by the manufacturer (Ͻ66 pmol/L; Ͻ18 pg/mL). However, Architect i2000 did not give results under the detection limits programmed into the analyzer: E 2 , Ͻ66 pmol/L (Ͻ18 pg/mL); P, Ͻ0.32 nmol/L (Ͻ0.1 ng/mL).
Functional sensitivities were 20 pmol/L (5.5 pg/mL; Kryptor) to 169 pmol/L (46 pg/mL; Architect i2000) for E 2 and 0.32 nmol/L (0.1 ng/mL; Kryptor) to 1.43 nmol/L (0.45 ng/mL; ACS-180) for P.
The functional sensitivities of direct E 2 and P immunoassays were two-to fourfold higher than the detection limits of these tests. A detection limit is generally defined by the manufacturer and cited alone in the package insert. This leads clinical laboratories to adopt an inappropriate detection limit on a patient's report, and unresolved questions remain concerning the use of these methods for clinical situations requiring assays with high sensitivity (16 ) .
Assuming that the same (or very similar) calibrators are used (gravimetric weighing of the pure analyte, dissolution in a suitable solvent before the preparation of serum calibrators, and testing against the isotope dilution-gas chromatography-mass spectrometry reference method), differences between assays lead to calibration having different matrix effects (ionic strength, pH, and protein concentration) (17 ) .
Other possible reasons for the differences observed between assays are the characteristics of the different antibodies and their different affinities and titers, along with specificity (18 -20 ) . However, we observed no clear difference between assays using monoclonal antibodies (Architect i2000 for E 2 and P; AxSYM, Immuno-1, ACS-180, and Advia-Centaur for P) and those using polyclonal antibodies (Coatria 125 I, Vitros ECi, and Kryptor for E 2 and P; Elecsys 2010, Immuno-1, IMx, ACS-180, and Advia-Centaur for E 2 ). We found no difference among the results obtained by the isotope method (Coatria 125 I) and chemiluminescence, electrochemiluminescence, fluorescence, or spectrophotometry methods, but we did find a difference between the results obtained with the Trace technology (Kryptor) and those obtained with all other methods. Trace seems to be the most sensitive detection system among the E 2 and P immunoassays tested.
None of the E 2 and P assays tested seemed to have the functional sensitivity required for the evaluation of E 2 and P in sera from children or of E 2 in sera from men. These assays have been optimized for clinical applications in which high concentrations are expected (e.g., E 2 determination for the monitoring of ovarian stimulation), and it is important to consider functional sensitivities as the lowest measurable concentrations. However, these tests could be used for determinations in sera from women to evaluate down-regulation before (E 2 ) and during (P) ovarian stimulation. In such cases, despite the low precision obtained in these concentration ranges (CV, ϳ 10 -15%), these rapid procedures are convenient for clinicians (results are available within 1 h). Although these automated systems are easy to use, with short cycle times and low costs, their use should be avoided for sera in which low concentrations are expected. We did not analyze testosterone in this study, but all the problems raised for E 2 and P also apply to testosterone, especially in the concentration range found in women (12 ) . We hope that manufacturers will soon agree to include the determination of functional sensitivity in package inserts to enlighten users concerning the limitations of these assays. Indeed, a collaborative We thank the following manufacturers for supplying the assay reagents and systems free of charge: Abbott Laboratories, Bayer Diagnostics, Bio-Merieux, Brahms, OrthoClinical Diagnostics, and Roche Diagnostics.
